Cargando…
Wegener's granulomatosis: current and upcoming therapies
Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that c...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165064/ https://www.ncbi.nlm.nih.gov/pubmed/12823849 http://dx.doi.org/10.1186/ar771 |
_version_ | 1782120829380722688 |
---|---|
author | Langford, Carol A |
author_facet | Langford, Carol A |
author_sort | Langford, Carol A |
collection | PubMed |
description | Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that can reduce the toxicity of therapy and lessen the likelihood of relapse. With the growth of knowledge regarding disease pathophysiology and the increasing ability to selectively target the immune system, the potential options for therapeutic investigation have continued to expand. Careful study of new agents through rigorously designed trials is essential to answering questions of safety and efficacy in Wegener's granulomatosis. |
format | Text |
id | pubmed-165064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1650642003-07-12 Wegener's granulomatosis: current and upcoming therapies Langford, Carol A Arthritis Res Ther Review Wegener's granulomatosis is a complex multisystem disease that can be associated with morbidity and mortality. The introduction of cyclophosphamide and glucocorticoids brought about the potential for long-term survival and provided the opportunity and impetus to explore treatment options that can reduce the toxicity of therapy and lessen the likelihood of relapse. With the growth of knowledge regarding disease pathophysiology and the increasing ability to selectively target the immune system, the potential options for therapeutic investigation have continued to expand. Careful study of new agents through rigorously designed trials is essential to answering questions of safety and efficacy in Wegener's granulomatosis. BioMed Central 2003 2003-05-29 /pmc/articles/PMC165064/ /pubmed/12823849 http://dx.doi.org/10.1186/ar771 Text en |
spellingShingle | Review Langford, Carol A Wegener's granulomatosis: current and upcoming therapies |
title | Wegener's granulomatosis: current and upcoming therapies |
title_full | Wegener's granulomatosis: current and upcoming therapies |
title_fullStr | Wegener's granulomatosis: current and upcoming therapies |
title_full_unstemmed | Wegener's granulomatosis: current and upcoming therapies |
title_short | Wegener's granulomatosis: current and upcoming therapies |
title_sort | wegener's granulomatosis: current and upcoming therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165064/ https://www.ncbi.nlm.nih.gov/pubmed/12823849 http://dx.doi.org/10.1186/ar771 |
work_keys_str_mv | AT langfordcarola wegenersgranulomatosiscurrentandupcomingtherapies |